U.S. Telecom Services and Carriers Stock News

Martin Midstream Partners (MMLP) opened 2026 with Q1 results that keep the focus squarely on profitability, as the latest trailing 12 month figures show total revenue of US$716.1 million and a loss of US$14.4 million, or basic EPS of US$0.37. Over recent quarters, the partnership has seen quarterly revenue range from US$168.7 million to US$192.5 million, while basic EPS has moved between a profit of US$0.09 and losses of up to US$0.21. This sets up an earnings release where investors are...

Rezolve AI (RZLV) drew fresh attention after announcing its brainpowa commerce-tuned AI model suite is now available within Microsoft Foundry, giving brands access to commerce-focused copilots deployed directly on Microsoft Azure. See our latest analysis for Rezolve AI. Despite the Microsoft Foundry news and a last close of $2.60, Rezolve AI’s recent momentum has been mixed, with a 1-month share price return of 1.17% but a 90-day share price decline of 17.20%, alongside a 1-year total...

Lake Shore Bancorp (LSBK) has just wrapped up Q4 2025 with total revenue of US$7.3 million, basic EPS of US$0.26 and net income of US$1.9 million, while trailing twelve month figures show revenue of US$28.0 million and EPS of US$0.97, alongside 47.4% earnings growth over the past year. Over recent quarters, the company has seen revenue move from US$6.4 million and EPS of US$0.17 in Q3 2024 to US$7.7 million and EPS of US$0.32 in Q3 2025, before settling at Q4 2025 levels. This progression...

Origin Bancorp (OBK) has just posted Q1 2026 results with revenue of US$99.1 million and Basic EPS of US$0.89, setting the tone for how the year is starting after a run of solid quarterly contributions to trailing 12 month EPS of US$2.60 and net income of US$80.5 million. Over recent quarters, revenue has moved from US$83.4 million in Q4 2024 to US$90.6 million in Q1 2025 and US$99.8 million in Q4 2025. Quarterly Basic EPS has ranged from US$0.46 to US$0.95 across that same stretch, giving a...

Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI achieved a 20% objective response rate, 87% disease control rate, and manageable safety in heavily pretreated patients with unresectable colorectal cancer, while also advancing a Biologics License Application for ozekibart in conventional chondrosarcoma. These data position ozekibart as a potential first-in-class DR5 agonist with activity across multiple hard-to-treat solid...

Popular (BPOP) has just posted another solid quarter, with Q4 2025 revenue of US$751.8 million and basic EPS of US$3.54, setting the tone as investors look at the new Q1 2026 reporting period. The bank has seen quarterly revenue move from US$689.4 million in Q4 2024 to US$751.8 million in Q4 2025, while basic EPS over that same stretch climbed from US$2.51 to US$3.54, giving you a clear sense of how the income line has scaled alongside the top line. Taken together with an improved net profit...

Katahdin Bankshares (KTHN) has just put another quarter on the board, with Q4 2025 revenue of US$11.9 million and basic EPS of US$0.99 setting the tone after a year in which trailing net income reached US$10.7 million on revenue of US$44.3 million. Over recent periods the company has seen revenue move from US$9.5 million and EPS of roughly US$0.56 in Q4 2024 to US$11.9 million and US$0.99 respectively in Q4 2025. Trailing basic EPS for the last reported twelve months reached about US$3.37...

American Riviera Bancorp (ARBV) opened 2026 with Q1 results that build on a solid finish to last year, with Q4 2025 revenue at about US$14.4 million and basic EPS of roughly US$0.80, while trailing twelve month revenue stood at about US$50.4 million and EPS at roughly US$2.18. Over recent quarters, revenue has moved from about US$10.7 million in Q4 2024 to US$14.4 million in Q4 2025, and basic EPS has shifted from roughly US$0.35 to US$0.80. This sets up a story where higher net income and...

Recently, Surgery Partners reduced its earnings guidance after encountering slower surgical case growth, a less favorable payer mix, and reimbursement pressures across its facilities. An important angle is that the company is still prioritizing higher-acuity procedures and robotics investments, suggesting a focus on reshaping its case mix despite these operational challenges. We’ll now explore how this guidance cut, driven by slower case growth and payer mix headwinds, affects Surgery...

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...

Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...

Farmers & Merchants Bancorp (FMAO) has put fresh numbers on the board, with Q4 2025 revenue of about US$31.9 million and basic EPS of US$0.70, supported by net income of US$9.7 million as the latest marker ahead of its Q1 2026 reporting period. The business has seen revenue move from US$26.6 million and EPS of US$0.59 in Q4 2024 to US$31.9 million and EPS of US$0.70 in Q4 2025. Trailing 12 month earnings growth of 29.4% and a 27.6% net margin frame a profitability profile that many investors...

Southern Missouri Bancorp (SMBC) opened Q3 2026 with Q2 results that put revenue and earnings in clear focus, reporting total revenue of US$48.0 million and basic EPS of US$1.62 on net income of US$18.1 million. The company has seen revenue move from US$41.7 million with EPS of US$1.10 in Q1 2025 to US$45.1 million and EPS of US$1.40 in Q4 2025, then to US$48.0 million and EPS of US$1.62 in Q2 2026. This latest report can be viewed as part of a steady earnings story that investors can now...

Carter Bankshares (CARE) opened Q1 2026 reporting Total Revenue of US$42.1 million in Q4 2025 and Basic EPS of US$0.38, with trailing twelve month EPS at US$1.38 and net income of US$31.0 million framing the latest run rate. Over the past year, Total Revenue on a trailing basis has moved from US$140.9 million to US$157.1 million while Basic EPS has shifted from US$1.06 to US$1.38, alongside earnings growth of 27.7% and net profit margin stepping up from 17.2% to 19.7%. For investors, these...

Republic Bancorp (RBCA.A) set the tone for Q1 2026 with recent results that sit against a trailing twelve month backdrop of US$385.9 million in revenue and basic EPS of US$6.65, underpinned by net income of US$131.3 million. Over the last few quarters, revenue has ranged from US$76.6 million to US$118.2 million per quarter while basic EPS moved between US$0.97 and US$2.40, giving investors a clear view of how the top and bottom lines have trended into the latest release. With a 34% net profit...

ONE Gas (OGS) has drawn fresh attention after its recent trading session, with the stock closing at $88.76. For investors, the move brings added focus to how the regulated utility’s fundamentals line up. See our latest analysis for ONE Gas. The latest move to $88.76 comes after a 14.93% 90 day share price return and a 16.97% total shareholder return over the past year, hinting that momentum has been building rather than fading. If this kind of steady utility performance has you thinking about...

MarineMax (HZO) has just posted its latest quarterly results, with Q1 2026 revenue of US$505.2 million and a basic EPS loss of US$0.36, alongside same store sales growth of 10.7%. The company has reported revenue of US$563.1 million in Q4 2024, US$631.5 million in Q2 2025, US$657.2 million in Q3 2025, US$552.2 million in Q4 2025, and US$505.2 million in Q1 2026, while EPS has ranged from a profit of US$0.80 in Q1 2025 to a loss of US$2.42 in Q3 2025. Margins remain under pressure, so this...

Thermo Fisher Scientific (TMO) has just put fresh numbers on the table, with Q4 2025 revenue of US$12.2b and basic EPS of US$5.22 setting the tone against a trailing twelve month EPS of US$17.78 on revenue of US$44.6b, alongside net income of US$6.7b. The company has seen quarterly revenue move from US$10.6b in Q3 2024 to US$12.2b in Q4 2025, while basic EPS over the same period went from US$4.27 to US$5.22. This gives investors a clear read on top line scale and earnings power as they assess...

Kearny Financial (KRNY) has just reported Q3 2026 results with quarterly revenue in the low US$40 million range and basic EPS of about US$0.15, set against a trailing twelve month EPS of US$0.52 that reflects the shift back into profitability. Over recent periods, revenue has moved from US$36.96 million in Q1 2025 to US$42.97 million in Q2 2026, while quarterly EPS has stepped from roughly US$0.10 to just over US$0.15. This gives investors a clearer read on how earnings now sit relative to...

First Bancorp (FBNC) opened 2026 with Q1 results that put the focus squarely on the income statement, reporting total revenue of US$119.2 million and basic EPS of US$1.13, backed by trailing twelve month revenue of US$393.3 million and EPS of US$2.93. Over recent periods the company has seen quarterly revenue move from US$65.2 million in Q4 2024 to US$104.7 million in Q1 2025, US$108.8 million in Q2, US$86.2 million in Q3 and US$79.2 million in Q4, while EPS shifted from US$0.09 to US$0.88,...

Investors may be wondering if Bristol-Myers Squibb at around US$59 a share still offers value, or if most of the opportunity is already priced in. The stock has returned 0.1% over the past week, 2.8% over the past month, 10.4% year to date and 27.3% over the last year, which naturally raises questions about what is currently baked into expectations. Recent attention on large pharmaceutical names, including Bristol-Myers Squibb, has centered on their pipelines, patent cycles and the role of...

Why Monolithic Power Systems Stock Is Back in Focus Ahead of Earnings Investor attention around Monolithic Power Systems (MPWR) has picked up as the company approaches its next quarterly report, following upbeat Q4 2025 results and positive guidance for Q1 2026 revenue of US$770 million to US$790 million. See our latest analysis for Monolithic Power Systems. The recent enthusiasm around earnings has coincided with strong momentum, with a 30 day share price return of 44.53% and a 1 year total...

Belite Bio recently initiated a rolling New Drug Application submission to the U.S. FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1, following completion of a Phase 3 trial and multiple regulatory designations including Breakthrough Therapy and Orphan Drug status. This step positions tinlarebant as a potential first approved treatment for Stargardt disease and highlights Belite Bio’s advancing regulatory and commercialization plans in rare retinal...

Northrim BanCorp (NRIM) opened 2026 with Q1 results anchored by a loan book of US$2.4b and a net interest margin of 4.77%, setting the tone for how its earnings engine is currently running. Over recent quarters, the bank has seen total revenue range from US$42.7m in Q4 2024 to US$64.9m in Q3 2025, while trailing twelve month net income reached US$64.6m, giving investors a clear view of how profits are tracking into the new year. With a cost to income ratio of 61.81% in Q1 2026 and non...